Neal Shore, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Myovant
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Moivant
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Genomic Health
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Guardant
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Urogen
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Pfizer
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Specialty Not Specified)
    Ineligible company:
    Genentech
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Astra Zeneca
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Merck
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    AstraZeneca
    Date added:
    Date updated:
    04/10/2024

Pages

Return to Operationalizing Checkpoint Inhibitors in Urologic Practice Webcast (2022)